MediciNova Inc (MNOV)
MediciNova Inc. is a NASDAQ-listed biopharmaceutical company focused on advancing therapies for serious diseases with limited treatment options. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective candidate in Phase 2 testing for a range of neurological and other conditions, including progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and the prevention of acute respiratory distress syndrome. It is also developing MN-001 (tipelukast), an oral small-molecule candidate in Phase 2 studies for fibrotic and metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. MediciNova was incorporated in 2000 and is based in La Jolla, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MNOV
|
$1.74
|
-47.6% Downside
|
Overvalued
|
$8.25
|
148.5% Upside
|
Bargain
|
Good
|
0.0%
|
November 12, 2026
|
4.6x
|
184.5x
|
163.4 M
|
144.5 M
|
0.1%
|
85.8%
|
9.2
|
84.9%
|
